Notably, B7 did not alter the populations of T cells, B cells, macrophages, and monocytes with or without CD155 overexpression (Figure S6, Supporting Information), suggesting that B7 exerts its therapeutic effects through a selective modulation of NK cell recruitment in the glioma TIME. The gene discussed is CD80; the disease is glioma.